Vancouver Biotech (Canada)

Performance of the 2025 ASAS-Spartan Revised Classification Criteria for Axial Spondyloarthritis in a Canadian Multicenter Inception Cohort with Psoriasis, Uveitis, or Colitis Presenting with Undiagnosed Back Pain

Objectives To test the performance of the 2025 ASAS-SPARTAN Revised Classification Criteria for Axial Spondyloarthritis (axSpA)[1] in a multicenter inception cohort of patients with undiagnosed chronic back pain attending dermatology, ophthalmology, and gastroenterology clinics w...